A few years ago, I bought myself a fitness watch. As I worked to rebuild my health after being diagnosed with metabolic dysfunction-associated steatohepatitis…
Fatty liver disease
FATTY LIVER DISEASE
NewsCombination of aerobic, resistance exercise best for reducing liver fat
A combination of aerobic exercise and resistance exercise is most effective for reducing liver fat, according to a review of data from appropriately controlled clinical…
FATTY LIVER DISEASE
ColumnsGetting ahead of concerns about fatty liver disease in children
Growing up, I was very much a daddy’s girl. My dad had a lively personality that helped him make instant friends wherever he went, sometimes…
FATTY LIVER DISEASE
ColumnsThink smoking only affects your lungs? Your liver would like a word.
When a new year rolls around, many of us naturally turn our attention to health. I’ve made enough resolutions over the years to know that…
FATTY LIVER DISEASE
NewsMadrigal acquires ervogastat to help boost MASH treatment options
Madrigal Pharmaceuticals, the maker of Rezdiffra (resmetiron), has acquired three new experimental treatments for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…
FATTY LIVER DISEASE
ColumnsCould GLP-1 medications be the future of fatty liver disease treatment?
Humans tend to love animals — especially the fuzzy, cuddly kind. I’m no exception. Anyone who knows me knows my devotion to my three cats:…
FATTY LIVER DISEASE
NewsPemvidutide advances toward Phase 3 after strong MASH fibrosis results
About one year of treatment with Altimmune’s experimental therapy pemvidutide led to reductions in noninvasive markers of liver scarring (fibrosis) in people with metabolic…
LIVER DISEASE
NewsTop 10 Liver Disease News stories of 2025
Throughout 2025, the team at Liver Disease News has reported on the latest research and advances in care related to various rare and non-rare liver…
FATTY LIVER DISEASE
NewsWegovy cleared in Canada to treat fatty liver disease MASH
Health Canada has conditionally approved Novo Nordisk’s Wegovy (semaglutide) to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. The…
FATTY LIVER DISEASE
NewsFDA authorizes use of 1st AI tool to speed MASH clinical trials
The U.S. Food and Drug Administration (FDA) has authorized the use of the first artificial intelligence (AI) drug-development tool for use in clinical trials of metabolic…
Recent Posts
- ALF marks Donate Life Month in April with focus on living liver donors
- Why we might cancel a doctor’s appointment (and why we shouldn’t)
- Inflammation markers may predict fetal risk in ICP: Study
- My son’s stubborn determination will aid him in his battle with liver disease
- Heavy episodic drinking raises odds of liver scarring in MASLD patients